Key experts in the fields of cardiology, diabetology and hypertension management, presented a comprehensive programme to more than 120 delegates from the Asia Pacific region. Main topics were the benefits of Adalat®, Aspirin®, and Glucobay®, not only as risk factor-targeted treatment strategies but also as agents of choice for long term cardiovascular disease (CVD) prevention were.
Carlo Patrono (Italy) took a mechanistic look at target patient groups for Aspirin® intervention based on risk/benefit assessments, and reviewed the growing evidence supporting the role of Aspirin® in primary prevention. The recently started ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial will help to fill the knowledge gap for the role of Aspirin® in patients at intermediate risk of future CV events.
Peter Meredith (UK) presented data to support the use of a combined antihypertensive treatment strategy – a concept recommended by current European guidelines. Adalat® is proven as a safe and effective treatment partner for the management of hypertension and CVD, and findings from the recently initiated TALENT (A Multicentre Study Evaluating Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies) study will further strengthen Adalat® ’s benefits with practising physicians.
Presenting the rationale for ACE (Acarbose Cardiovascular Evaluation), Jean-Louis Chiasson (Canada) reviewed the evidence that prediabetes is a growing condition, and that its diagnosis and treatment are increasingly recognised as fundamental to reducing the risk of developing type 2 diabetes and CV complications. Glucobay® is a well established agent for the management of postprandial hyperglycaemia among physicians in the Asia Pacific region. ACE will help to translate the effects of Glucobay® on glycaemic control into the CV risk reduction benefits already demonstrated in the STOP-NIDDM study.
